GW Pharmaceuticals PLC (NASDAQ:GWPH) was upgraded by investment analysts at Vetr from a “buy” rating to a “strong-buy” rating in a report released on Tuesday. The brokerage currently has a $141.40 price target on the biopharmaceutical company’s stock. Vetr‘s price objective would indicate a potential upside of 12.93% from the stock’s previous close.

Several other research firms also recently commented on GWPH. Goldman Sachs Group Inc. assumed coverage on GW Pharmaceuticals PLC in a research note on Friday, October 7th. They issued a “buy” rating and a $189.00 price objective on the stock. Leerink Swann assumed coverage on GW Pharmaceuticals PLC in a research report on Tuesday, October 4th. They set an “outperform” rating and a $162.00 target price for the company. Piper Jaffray Cos. reiterated an “overweight” rating and set a $147.00 target price on shares of GW Pharmaceuticals PLC in a research report on Monday, September 26th. Cowen and Company reiterated an “outperform” rating and set a $135.00 target price on shares of GW Pharmaceuticals PLC in a research report on Tuesday, September 27th. Finally, Morgan Stanley increased their target price on GW Pharmaceuticals PLC from $152.00 to $160.00 and gave the stock an “overweight” rating in a research report on Sunday, September 25th. One analyst has rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $143.40.

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) traded down 1.31% on Tuesday, hitting $125.21. The stock had a trading volume of 359,535 shares. The firm has a 50-day moving average price of $113.58 and a 200-day moving average price of $93.44. The stock’s market capitalization is $2.74 billion. GW Pharmaceuticals PLC has a 52 week low of $35.83 and a 52 week high of $137.88.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.21) by $1.15. GW Pharmaceuticals PLC had a negative return on equity of 26.26% and a negative net margin of 409.40%. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.63 million. During the same quarter in the prior year, the company earned ($0.09) earnings per share. GW Pharmaceuticals PLC’s revenue was down 73.3% on a year-over-year basis. Equities analysts expect that GW Pharmaceuticals PLC will post ($4.52) earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. Advisory Services Network LLC boosted its position in shares of GW Pharmaceuticals PLC by 1,109.2% in the third quarter. Advisory Services Network LLC now owns 786 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 721 shares during the period. Seven Eight Capital LLC boosted its position in shares of GW Pharmaceuticals PLC by 216.7% in the first quarter. Seven Eight Capital LLC now owns 1,900 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 1,300 shares during the period. IFP Advisors Inc boosted its position in shares of GW Pharmaceuticals PLC by 5.7% in the second quarter. IFP Advisors Inc now owns 1,859 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 100 shares during the period. Rothschild Investment Corp IL bought a new position in shares of GW Pharmaceuticals PLC during the second quarter worth approximately $200,000. Finally, HighTower Advisors LLC bought a new position in shares of GW Pharmaceuticals PLC during the second quarter worth approximately $203,000. Hedge funds and other institutional investors own 68.50% of the company’s stock.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.

5 Day Chart for NASDAQ:GWPH

Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.